GSK’s Pre-Pandemic Flu Vaccine To Get Priority Review In Japan
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Reflecting its growing concerns about new types of influenza outbreaks, Japan's Ministry of Health, Labor and Welfare will conduct a priority review of GlaxoSmithKline K.K.'s pre-pandemic vaccine, a GSK spokesman and ministry officials said Sept. 5
You may also be interested in...
GSK Forms Joint Venture With Shenzhen Neptunus Interlong Bio-Technique For Flu Vaccine
HONG KONG - GlaxoSmithKline announced Nov. 21 a joint venture with Shenzhen Neptunus Interlong Bio-Technique to develop flu vaccines aimed at strains specific to China, Hong Kong and Macau
GSK Forms Joint Venture With Shenzhen Neptunus Interlong Bio-Technique For Flu Vaccine
HONG KONG - GlaxoSmithKline announced Nov. 21 a joint venture with Shenzhen Neptunus Interlong Bio-Technique to develop flu vaccines aimed at strains specific to China, Hong Kong and Macau
Aussie Biotech Biota Completes Phase II Trials for Relenza Follow-On; Phase III To Be Conducted In Japan, Taiwan, Hong Kong and Korea
PERTH, Australia - Australian biotech Biota completed Phase II trials for its second-generation influenza compound CS-8958; the trials successfully met all endpoints, the company announced July 31